Impact of telmisartan in modifying vascular risk

References

• ManciaGDe BackerGDominiczakAfor Management of Arterial Hypertension of the European Society of Hypertension and European Society of Cardiology2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2007251105118717563527
   PubMed Web of Science ®Google Scholar
• De BackerGAmbrosioniEBorch-JohnsenKfor Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical PracticeEuropean guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practiceEur Heart J2003241601161012964575
   PubMed Web of Science ®Google Scholar
• MazzagliaGAmbrosioniEAlacquaMAdherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patientsCirculation20091201598160519805653
   PubMed Web of Science ®Google Scholar
• ChapmanRHFerrufinoCPKowalSLClassiPRobertsCSThe cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugsInt J Clin Pract20106416918120089007
   PubMed Web of Science ®Google Scholar
• BurnierMBrunnerHRAngiotensin II receptor antagonistsLancet200035563764510696996
   PubMed Web of Science ®Google Scholar
• VanderheydenPMFierensFLVauquelinGAngiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibitionBiochem Pharmacol2000601557156311077037
   PubMed Web of Science ®Google Scholar
• SongJCWhiteCMOlmesartan medexomil (CS-866) an angiotensin II receptor blocker for treatment of hypertensionFormulary2001236487499
   Google Scholar
• KakutaHSudohKSasamataMYamagishiSTelmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockersInt J Clin Pharmacol Res200525414615864875
   PubMedGoogle Scholar
• GoebelMClemenzMUngerTEffective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartanExpert Rev Cardiovasc Ther2006461562917081084
   PubMedGoogle Scholar
• MaillardMPPerregauxCCentenoCIn vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonistJ Pharmacol Exp Ther20023021089109512183667
   PubMed Web of Science ®Google Scholar
• RemkováAKratochvíl’ováHDurinaJImpact of the therapy by renin-angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertensionJ Hum Hypertens20082233834518305548
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activityHypertension200443993100215007034
   PubMed Web of Science ®Google Scholar
• PershadsinghHAKurtzTWInsulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular diseaseDiabetes Care200427101515047668
   PubMed Web of Science ®Google Scholar
• MiuraYYamamotoNTsunekawaSReplacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequencesDiabetes Care20052875775815735228
   PubMed Web of Science ®Google Scholar
• VitaleCMercuroGCastiglioniCMetabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeCardiovasc Diabetol200515615892894
   PubMed Web of Science ®Google Scholar
• AbuissaHJonesPGMarsoSPO’KeefeJHAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trialsJ Am Coll Cardiol20054682182616139131
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJfor ONTARGET InvestigatorsTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med200034214515310639539
   PubMed Web of Science ®Google Scholar
• DellesCRaffUMimranAFauvelJPRuilopeLMSchmiederREEffects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetesAm J Hypertens2008211330133618989258
   PubMed Web of Science ®Google Scholar
• HopkinsTAOuchiNShibataRWalshKAdiponectin actions in the cardiovascular systemCardiovasc Res200774111817140553
   PubMed Web of Science ®Google Scholar
• SchmiederREDellesCMimranAFauvelJPRuilopeLMImpact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetesDiabetes Care2007301351135617337492
   PubMed Web of Science ®Google Scholar
• BaguetJPLegallicierBAuquierPRobitailSUpdated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressureClin Drug Investig200727735753
   PubMed Web of Science ®Google Scholar
• LacourcièreYNeutelJMDavidaiGKovalSA multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoringAm J Hypertens20061910411216461201
   PubMed Web of Science ®Google Scholar
• WilliamsBGossePLoweLHarperRfor PRISMA I Study GroupThe prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I)J Hypertens20062419320016331118
   PubMed Web of Science ®Google Scholar
• GossePNeutelJMSchumacherHLacourcièreYWilliamsBDavidaiGThe effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trialsBlood Press Monit20071214114717496463
   PubMed Web of Science ®Google Scholar
• WhiteWBMurwinDChrysantSGKovalSEDavidaiGGuthrieREffects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trialBlood Press Monit200813212718199920
   PubMed Web of Science ®Google Scholar
• MallionJSichéJLacourcièreYABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertensionJ Hum Hypertens19991365766410516734
   PubMed Web of Science ®Google Scholar
• BakrisGComparison of telmisartan vs valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoringJ Clin Hypertens (Greenwich)20024 Suppl 1S26S31
   Google Scholar
• NeutelJMLittlejohnTWChrysantSGSinghAfor Telmisartan Study GroupTelmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertensionHypertens Res20052855556316335883
   PubMed Web of Science ®Google Scholar
• SharmaAMDavidsonJKovalSLacourcièreYTelmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH studyCardiovasc Diabetol200762817910747
   PubMed Web of Science ®Google Scholar
• NeldamSEdwardsCfor ATHOS Study GroupTelmisartan plus HCTZ vs amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring studyAm J Geriatr Cardiol20061515116016687967
   PubMed Web of Science ®Google Scholar
• ManciaGParatiGBiloGEffects of ramipril, telmisartan and their combination on ambulatory blood pressure in an ONTARGET substudy [abstract]J Hypertens200927Suppl 4S168
   Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension task force documentJ Hypertens2009272121215819838131
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDfor RENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med200134586186911565518
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRfor Collaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med200134585186011565517
   PubMed Web of Science ®Google Scholar
• ParvingHHLehnertHBröchner-MortensenJGomisRAndersenSArnerPfor Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study GroupThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetesN Engl J Med200134587087811565519
   PubMed Web of Science ®Google Scholar
• MakinoHHanedaMBabazonoTfor INNOVATION Study GroupPrevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetesDiabetes Care2007301577157817389334
   PubMed Web of Science ®Google Scholar
• BarnettAHBainSCBouterPfor Diabetics Exposed to Telmisartan and Enalapril Study GroupAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med20043511952196115516696
   PubMed Web of Science ®Google Scholar
• BakrisGBurgessEWeirMDavidaiGKovalSfor AMADEO Study InvestigatorsTelmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyKidney Int20087436436918496508
   PubMed Web of Science ®Google Scholar
• GalleJSchwedhelmEPinnettiSBögerRHWannerCfor VIVALDI investigatorsAntiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathyNephrol Dial Transplant2008233174318318450829
   PubMed Web of Science ®Google Scholar
• VogtLNavisGKösterJManolisAJReidJLde ZeeuwDfor Angiotensin II Receptor Antagonist telmisartan Micardis in Isolated Systolic hypertension (ARAMIS) study groupThe angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trialJ Hypertens2005232055206116208149
   PubMed Web of Science ®Google Scholar
• KunzRFriedrichCWolbersMMannJFMeta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal diseaseAnn Intern Med2008148304817984482
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMfor ONTARGET investigatorsRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multi-centre, randomised, double-blind, controlled trialLancet200837254755318707986
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGfor Valsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med20013451667167511759645
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKfor CHARM Investigators and CommitteesEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet200336276777113678869
   PubMed Web of Science ®Google Scholar
• GalzeranoDTammaroPCercielloAFreehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre studyJ Hum Hypertens200418535914688811
   PubMed Web of Science ®Google Scholar
• GalzeranoDTammaroPdel ViscovoLThree-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal studyAm J Hypertens2005181563156916364826
   PubMed Web of Science ®Google Scholar
• PetrovicIPetrovicDVukovicNVentricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patientsJ Int Med Res200533Suppl 139A49A
   PubMed Web of Science ®Google Scholar
• YusufSTeoKAndersonCfor Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet20083721174118318757085
   PubMed Web of Science ®Google Scholar
• VerdecchiaPSleightPManciaGfor ONTARGET/TRANSCEND InvestigatorsEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular diseaseCirculation20091201380138919770395
   PubMed Web of Science ®Google Scholar
• SleightPRedonJVerdecchiaPfor ONTARGET investigatorsPrognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial studyJ Hypertens2009271360136919506526
   PubMed Web of Science ®Google Scholar
• HealeyJSBaranchukACrystalEPrevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysisJ Am Coll Cardiol2005451832183915936615
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attackLancet20013581033104111589932
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLfor PRoFESS Study GroupTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med20083591225123718753639
   PubMed Web of Science ®Google Scholar
• GerthWCCompliance and persistence with newer antihypertensive agentsCurr Hypertens Rep2002442443312419170
   PubMed Web of Science ®Google Scholar